林書玉

SY Lin林書玉  助研究員
生技與藥物研究所
Email: shuyulin@nhri.edu.tw

 

EDUCATION

  • Ph.D., Chemistry, National Tsing Hua University, Hsinchu, Taiwan (2010).
  • M.S., Chemistry, National Tsing Hua University, Hsinchu, Taiwan (2005).
  • B.S. Chemistry, Tunghai University, Taichung, Taiwan (2003).

PROFESSIONAL EXPERIENCES

  • Assistant investigator, Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes (July. 2024–).
  • Associate Director II, Chemistry, BioDuro-Sundia, Wuxi site in Jiangsu (April 2023–May 2024).
  • Associate Director, Chemistry, Sundia Meditech USA, Inc., Taiwan Branch (Mar. 2020–Mar. 2023).
  • Postdoctoral Research Fellow, Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes (Aug 2011–Feb. 2020).
  • Postdoctoral Research Fellow, Department of Chemistry, National Tsing Hua University (Aug. 2010–July 2011).

RESEARCH INTERESTS

  • Design and development of novel therapeutic agents for cancer and metabolic diseases.
  • Overcoming drug resistance in cancer therapy.
  • Development of new synthetic methodologies and strategies for complex organic compound.

RESEARCH ACTIVITIES & ACCOMPLISHMENTS

Dr. Shu-Yu Lin is an Assistant Investigator at the Institute of Biotechnology and Pharmaceutical Research, where she brings a wealth of experience from the contract research organization (CRO) industry. With over two decades dedicated to the field of organic synthesis and drug development, Dr. Lin has made significant contributions to the advancement of therapeutic agents, particularly in immuno-oncology, analgesic, antiviral, and kinase inhibitors. Before joining the Institute, Dr. Lin served as an Associate Director II at BioDuro-Sundia focusing on innovative synthetic chemistry and drug discovery projects for international biotech and pharmaceutical companies. Dr. Lin’s current research at the Institute involves exploring novel molecular syntheses and applying advanced drug design principles to develop new therapeutic options for various diseases.

SELECTED PUBLICATIONS

  1. Yi-Han Huang, Shu-Yu Lin, Li-Chin, Ou, Wei-Cheng Huang, Po-Kuan Chao, Yung-Chiao Chang, Hsiao-Fu Chang, Pin-Tse Lee, Teng-Kuang Ye, Yu-Hsien Kuo, Ya-Wen, Tien, Jing-Hua Xi, Pao-Luh, Tao, Pin-Yuan Chen, Jian Ying Chuang, Chuan Shih, Chiung-Tong Chen, Chun-Wei Tung, Horace H. Lao, Shau-Hua Ueng*, Shiu-Hwa Yeh*. “Discovery of a mu-opioid receptor modulator that in combination with morphinan antagonists induces analgesia.” Cell Chem. Bio., 2024, accepted.
  2. Mu-Chun Li; Mohane Coumar, Shu-Yu Lin, Yih-Shyan Lin, Guan-Lin Huang, Chun-Hwa Chen, Tzu-Wen Lien, Yi-Wen Wu, Yen-Ting Chen, Ching-Ping Chen, Yu-Chen Huang, Kai-Chia Yeh, Chen-Ming Yang; Bikashita Kalita, Shiow-Lin Pan, Tsu-An Hsu, Teng-Kuang Yeh, Chiung-Tong Chen, Hsing-Pang Hsieh*. “Development of Furanopyrimidine-Based Orally Active Third-Generation EGFR Inhibitors for the Treatment of Non-Small Cell Lung Cancer.” J. Med. Chem. 2023, 66, 2566–2588.
  3. Shu-Yu Lin, Ya-Wen Tien, Yi-Yu Ke, Yung-Chiao Chang, Hsiao-Fu Chang, Li-Chin Ou, Ping-Yee Law, Jing-Hua Xi, Pao-Luh Tao, Horace H. Loh, Yu-Sheng Chao, Chuan Shih, Chiung-Tong Chen, Shiu-Hwa Yeh, Shau-Hua Ueng*. ”Selective and antagonist-dependent µ-opioid receptor activation by the combination of 2-{[2-(6-chloro-3,4-dihydro-1(2H)-quinolinyl)-2-oxoethyl]sulfanyl}-5-phenyl-4,6-(1H,5H)-pyrimidinedione and naloxone/naltrexone.” Bioorg. Chem. 2022, 128, 105905.
  4. Shu-Yu Lin, Chun-Feng Chang, Mohane Selvaraj Coumar, Pei-Yi Chen, Fu-Ming Kuo, Chun-Hwa Chen, Mu-Chun Li, Wen-Hsing Lin, Po-Chu Kuo, Sing-Yi Wang, An-Siou Li, Chin-Yu Lina, Chen-Ming Yang, Teng-Kuang Yeh, Jen-Shin Song, John T.-A. Hsu, Hsing-Pang Hsieh*. “Drug-Like Property Optimization: Discovery of Orally Bioavailable Quinazoline-Based Multi-Targeted Kinase Inhibitors.” Bioorg. Chem. 2020, 98, 103689.
  5. Shu-Yu Lin, Yung Chang Hsu, Yi-Hui Peng, Yi-Yu Ke, Wen-Hsing Lin, Hsu-Yi Sun, Fu-Ming Kuo, Pei-Yi Chen, Tzu-Wen Lien, Chun-Hwa Chen, Chang-Ying Chu, Sing-Yi Wang, Kai-Chia Yeh, Ching-Ping Chen, Tsu-An Hsu, Su-Ying Wu, Teng-Kuang Yeh, Chiung-Tong Chen, Hsing-Pang Hsieh*.” Discovery of a Furanopyrimidine-Based Epidermal Growth Factor Receptor Inhibitor (DBPR112) as a Clinical Candidate for the Treatment of Non-Small Cell Lung Cancer.” J. Med. Chem. 2019, 62, 10108−10123.
  6. Shu-Yu Lin, Yu-Hsien Kuo, Ya-Wen Tien, Yi-Yu Ke, Wan-Ting Chang, Hsiao-Fu Chang, Li-Chin Ou, Ping-Yee Law, Jing-Hua Xi, Pao-Luh Tao, Horace H. Loh, Yu-Sheng Chao, Chuan Shih, Chiung-Tong Chen, Shiu-Hwa Yeh *, Shau-Hua Ueng*. “The in vivo Antinociceptive and μ-Opioid Receptor Activating Effects of the Combination of N-Phenyl-2’,4’-Dimethyl-4,5’-bi-1,3-Thiazol-2-Amines and Naloxone.” Eur. J. Med. Chem. 2019, 167, 312−323.
  7. Jih Ru Hwu*, Wen-Chieh Huang, Shu-Yu Lin, Kui-Thong Tan, Yu-Chen Hu, Fa-Kuen Shieh, Sergey O. Bachurin, Alexey Ustyugov, Shwu-Chen Tsay*. “Chikungunya Virus Inhibition by Synthetic Coumarine Guanosine Conjugates.” Eur. J. Med. Chem. 2019, 166, 136−143.
  8. Shu-Yu Lin, Teng-Kuang Yeh, Jen-Shin Song, Ming-Shiu Hung, Ming-Fu Cheng, Fang-Yu Liao,An-Shiou Li, Shu-Ying Cheng, Li-Mei Lin, Chun-Hsien Chiu, Mine-Hsine Wu, Yi-Jyun Lin, Wenchi Hsiao, Manwu Sun, Yi-Hsin Wang, Chin-Hsiang Huang, Ya-Chu Tang, Hsin-Huei Chang,Zih-Ting Huang, Yu-Sheng Chao, Chuan Shih, Shiow-Lin Pan, Su-Ying Wu, Ching-Chuan Kuo*, Shau-Hua Ueng*. “4-Bromophenylhydrazinyl benzenesulfonylphenyl-ureas as indoleamine 2,3-dioxygenase inhibitors with in vivo target inhibition and anti-tumor efficacy.” Bioorg. Chem. 2018, 77, 600−607.
  9. Sheng-Ren Chen, Yi-Yu Ke, Teng-Kuang Yeh, Shu-Yu Lin, Li-Chin Ou, Shu-Chun Chen, Wan-Ting Chang, Hsiao-Fu Chang, Zih-Huei Wu, Chih-Chien Hsieh, Ping-Yee Law, Horace H. Loh, Chuan Shih, Yiu-Kay Lai*, Shiu-Hwa Yeh*, Shau-Hua Ueng*. “Discovery, Structure-Activity Relationship Studies, and Anti-nociceptive Effects of N-(1,2,3,4-tetrahydro-1-isoquinolinylmethyl)- benzamides as Novel Opioid Receptor Agonists.” Eur. J. Med. Chem. 2017, 126, 202−217.
  10. Shwu-Chen Tsay*, Shu-Yu Lin, Wen-Chieh Huang, Ming-Hua Hsu, Kuo Chu Hwang, Chun-Cheng Lin, Jia-Cherng Horng, I-Chia Chen, Jih Ru Hwu*, Fa-Kuen Shieh, Pieter Leyssen, Johan Neyts*. “Synthesis and Structure-Activity Relationships of Imidazole-Coumarin Conjugates against Hepatitis C Virus.” Molecules, 2016, 21, 228.
  11. Shu-Yu Lin, Teng-Kuang Yeh, Ching-Chuan Kuo, Jen-Shin Song, Ming-Fu Cheng, Fang-Yu Liao, Min-Wu Chao, Han-Li Huang, Yi-Lin Chen, Chun-Yu Yang, Mine-Hsine Wu, Chia-Ling Hsieh, Wenchi Hsiao, Yi-Hui Peng, Jian-Sung Wu, Li-Mei Lin, Manwu Sun, Yu-Sheng Chao, Chuan Shih, Su-Ying Wu, Shiow-Lin Pan*, Ming-Shiu Hung*, Shau-Hua Ueng*. “Phenyl Benzenesulfonylhydrazides Exhibit Selective Indoleamine 2,3-Dioxygenase Inhibition with Potent in Vivo Pharmacodynamic Activity and Antitumor Efficacy.” J. Med. Chem. 2016, 59, 419−430.
  12. Yi-Hui Peng, Shau-Hua Ueng, Chen-Tso Tseng, Ming-Shiu Hung, Jen-Shin Song, Jian-Sung Wu, Fang-Yu Liao, Yu-Shiou Fan, Mine-Hsine Wu, Wen-Chi Hsiao, Ching-Cheng Hsueh, Shu-Yu Lin, Chia-Yi Cheng, Chih-Hsiang Tu, Lung-Chun Lee, Ming-Fu Cheng, Kak-Shan Shia, Chuan Shih, Su-Ying Wu*. “Important Hydrogen Bond Networks in Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Design Revealed by Crystal Structures of Imidazoleisoindole Derivatives with IDO1.” J. Med. Chem. 2016, 59, 282−293.
  13. Jian-Sung Wu, Shu-Yu Lin, Fang-Yu Liao, Wen-Chi Hsiao, Lung-Chun Lee, Yi-Hui Peng, Chia-Ling Hsieh, Mine-Hsine Wu, Jen-Shin Song, Andrew Yueh, Chun-Hwa Chen, Shiu-Hwa Yeh, Chia-Yeh Liu, Shu-Yi Lin, Teng-Kuang Yeh, John T.-A. Hsu, Chuan Shih, Shau-Hua Ueng*, Ming-Shiu Hung*, Su-Ying Wu*. “Identification of Substituted Naphthotriazolediones as Novel Tryptophan 2,3-Dioxygenase (TDO) Inhibitors through Structure-Based Virtual Screening.” J. Med. Chem. 2015, 58, 7807−7819.
  14. Ming-Fu Cheng, Ming-Shiu Hung, Jen-Shin Song, Shu-Yu Lin, Fang-Yu Liao, Mine-Hsine Wu, Wenchi Hsiao, Chia-Ling Hsieh, Jian-Sung Wu, Yu-Sheng Chao, Chuan Shih, Su-Ying Wu*, Shau-Hua Ueng*. “Discovery and Structure–Activity Relationships of Phenyl Benzenesulfonylhydrazides as Novel Indoleamine 2,3-Dioxygenase Inhibitors.” Bioorg. Med. Chem. Lett. 2014, 24, 403–3406.
  15. Jih Ru Hwu,* Shu-Yu Lin, Shwu-Chen Tsay, Erik De Clercq, Pieter Leyssen, Johan Neyts.  “Coumarin–Purine Ribofuranoside Conjugates as New Agents Against Hepatitis C Virus,” J. Med. Chem. 2011, 54, 2114–2126.

HONORS AND AWARDS

  • 2020 Ministry of Science and Technology Postdoctoral Researcher Academic Research Award

PATENT

  1. Ueng, S.-H.; Yeh, S.-H.; Lin, S.-Y.; Shih, C.; Loh, H. Thiazolidinone compounds and use thereof. KR10-2365673, 2022. (Granted)
  2. Ueng, S.-H.; Yeh, S.-H.; Lin, S.-Y.; Shih, C.; Loh, H. Preparation of thiazolidinone compounds and use thereof as opioid receptor modulators. CN201780015438.9, 2021. (Granted)
  3. Ueng, S.-H.; Yeh, S.-H.; Lin, S.-Y.; Shih, C.; Loh, H. Preparation of thiazolidinone compounds and use thereof as opioid receptor modulators. AU2017229129B2, 2021. (Granted)
  4. Ueng, S.-H.; Yeh, S.-H.; Lin, S.-Y.; Shih, C.; Loh, H. Preparation of thiazolidinone compounds and use thereof as opioid receptor modulators. US10,544,113B2, 2020. (Granted)
  5. 翁紹華、葉修華、林書玉、石全、羅浩，中華民國專利，噻唑烷酮化合物及其用途。TWI691332B，2020 年。(獲證)

BOOK

Organic Chemistry (including previous exam questions and solution manual),
Authors: Chih Hong Hsiao, Shu-Yu Lin, Second edition, July 2017.
Taiwan, Ting-Wen Co., Ltd.
ISBN: 9789574547777

Comments are closed.